Limitations
This study has some limitations. Our analysis was unplanned and exploratory in nature. Additionally, it had limited statistical power because there were only 53 patients without LM. Studies reporting differential impact with regard to the presence of LM are heterogeneous. It is possible that different ICIs may have different activity levels and our findings may be specific to durvalumab plus tremelimumab.